Google Groups no longer supports new Usenet posts or subscriptions. Historical content remains viewable.
Dismiss

Articles de revue sur le mélanome - Dernières parutions

0 views
Skip to first unread message

scim...@mail.com

unread,
May 28, 2008, 4:48:28 AM5/28/08
to

InTextoResearch, agence d'information scientifique


InTextoResearch vous informe sur les dernières parutions d'articles de
revue sur le mélanome (28 ami 2008):

The hunt for the secrets of uveal melanoma.
Shields CL.
Clin Experiment Ophthalmol. 2008 Apr;36(3):277-80.

Emerging therapies for melanoma.
Katipamula R, Markovic SN.
Expert Rev Anticancer Ther. 2008 Apr;8(4):553-60.

Nonsolar occupational risk factors for cutaneous melanoma.
Fortes C, de Vries E.
Int J Dermatol. 2008 Apr;47(4):319-28.

An unusual composite pilomatrix carcinoma with intralesional
melanocytes: differential diagnosis, immunohistochemical evaluation,
and review of the literature.
Jani P, Chetty R, Ghazarian DM.
Am J Dermatopathol. 2008 Apr;30(2):174-7.

Adoptive cell transfer: a clinical path to effective cancer
immunotherapy.
Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME.
Nat Rev Cancer. 2008 Apr;8(4):299-308.

Treatment of melanoma and nonmelanoma skin cancer.
Rass K, Tilgen W.
Adv Exp Med Biol. 2008;624:296-318.

Apoptosis and pathogenesis of melanoma and nonmelanoma skin cancer.
Erb P, Ji J, Kump E, Mielgo A, Wernli M.
Adv Exp Med Biol. 2008;624:283-95.

Molecular biology of malignant melanoma.
Pons M, Mancheño-Corvo P, Martín-Duque P, Quintanilla M.
Adv Exp Med Biol. 2008;624:252-64.

P53 protein and pathogenesis of melanoma and nonmelanoma skin cancer.
Benjamin CL, Melnikova VO, Ananthaswamy HN.
Adv Exp Med Biol. 2008;624:265-82.

Melanoma and nonmelanoma skin cancers and the immune system.
Domingo DS, Baron ED.
Adv Exp Med Biol. 2008;624:187-202.

Role of viruses in the development of squamous cell cancer and
melanoma.
Hengge UR.
Adv Exp Med Biol. 2008;624:179-86.

Novel therapies targeting the immune system: CTLA4 blockade with
tremelimumab (CP-675,206), a fully human monoclonal antibody.
Camacho LH.
Expert Opin Investig Drugs. 2008 Mar;17(3):371-85.

The MAPK pathway in melanoma.
Fecher LA, Amaravadi RK, Flaherty KT.
Curr Opin Oncol. 2008 Mar;20(2):183-9.

The role of vaccine therapy in the treatment of melanoma.
Lens M.
Expert Opin Biol Ther. 2008 Mar;8(3):315-23.

Epigenetic lesions in malignant melanoma.
Schwabe M, Lübbert M.
Curr Pharm Biotechnol. 2007 Dec;8(6):382-7.

BRAF kinase in melanoma development and progression.
DeLuca AM, Srinivas A, Alani RM.
Expert Rev Mol Med. 2008 Feb 18;10:e6.

Adjuvant radiotherapy for cutaneous melanoma.
Mendenhall WM, Amdur RJ, Grobmyer SR, George TJ Jr, Werning JW,
Hochwald SN, Mendenhall NP.
Cancer. 2008 Mar 15;112(6):1189-96.

Interleukin 21: combination strategies for cancer therapy.
Skak K, Kragh M, Hausman D, Smyth MJ, Sivakumar PV.
Nat Rev Drug Discov. 2008 Mar;7(3):231-40.

Practical guidelines for the management of interferon-alpha-2b side
effects in patients receiving adjuvant treatment for melanoma: expert
opinion.
Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dréno B,
Kirkwood JM.
Cancer. 2008 Mar 1;112(5):982-94.

Leptomeningeal melanoma of unknown primary site: two cases with an
atypical presentation of acute meningitis.
Levidou G, Korkolopoulou P, Papetta A, Patsouris E, Agapitos E.
Clin Neuropathol. 2007 Nov-Dec;26(6):299-305.


(contact pour InTextoResearch: Marc Lacroix, Baelen, Wallonie,
Belgique - scim...@mail.com)

0 new messages